HER2 status in gastric cancer: A comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest™)

Pathology Research and Practice

Volumn 209, Issue 9, 2013, Pages 548-554

  Pala, Emel Ebru ^a   Bayol, Umit ^a   Ozguzer, Alp ^a   Akman, Ozlem ^a  

^a Izmir Tepecik Training and Research Hospital   (Turkey)

Author keywords

Fluorescence in situ hybridization; Gastric carcinoma; HER2; Immunohistochemistry; Silver enhanced in situ hybridization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRECTOMY; GENE AMPLIFICATION; HER2 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; LABORATORY DEVICE; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SILVER ENHANCED IN SITU HYBRIDIZATION; STOMACH CANCER; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

FLUORESCENCE IN SITU HYBRIDIZATION; GASTRIC CARCINOMA; HER2; IMMUNOHISTOCHEMISTRY; SILVER-ENHANCED IN SITU HYBRIDIZATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS;

EID: 84883555079     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.05.008     Document Type: Article

References (33)

1. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
2. Owens M.A., Horten B.C., Da Silva M.M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin. Breast Cancer 2004, 5:63-69.
3. Tubbs R.R., Hicks D.G., Cook J., et al. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast: a single institution experience. Diagn. Mol. Pathol. 2007, 16:207-210.
4. Dietel M., Ellis I.O., Höfler H., et al. Comparison of automated silver enhanced in situ hybridization (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007, 451:19-25.
5. Hofmann M., Stoss O., Shi D., et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008, 52:797-805.
6. Takehana T., Kunitomo K., Kono K., et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization, and enzyme-linked immuno-sorbent assay. Int. J. Cancer 2002, 98:833-837.
7. Brien T.P., Depowski P.L., Sheehan C.E., Ross J.S., McKenna B.J. Prognostic factors in gastric cancer. Mod. Pathol. 1998, 11:870-877.
8. Risio M., De Rosa G., Sarotto I., et al. HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. Int. J. Oncol. 2003, 23:1381-1387.
9. Song Y., Huang J., Wang J.W. Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma. Ai Zheng 2010, 29:76-81.
10. Ishikawa T., Kobayashi M., Mai M., Suzuki T., Ooi A. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells, Detection by fluorescence in situ hybridization. Am. J. Pathol. 1997, 151:761-768.
11. Brien T.P., Odze R.D., Sheehan C.E., et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus associated adenocarcinoma. Hum. Pathol. 1999, 31:35-39.
12. Varis A., Zaika A., Puolakkainen P., et al. Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int. J. Cancer 2004, 109:548-553.
13. Tanner M., Hollme'n M., Junttila T.T., et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 2005, 16:273-278.
14. Yano T., Doi T., Ohtsu A., et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol. Rep. 2006, 15:65-71.
15. Schiavon B.N., Jasani B., de Brot L., et al. Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting: influence of poor tissue preservation. Am. J. Surg. Pathol. 2012, 36(10):1489-1496.
16. Bosman F.T., Carneiro F., Hruban R.H., Theise N.D. WHO Classification of Tumours of the Digestive System 2010, IARC Press, Lyon.
17. Kimura M., Tsuda H., Morita D., et al. A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch. 2004, 445:255-262.
18. Jorgensen J.T., Hersom M. HER2 as a prognostic marker in gastric cancer- a systematic analysis of data from the literature. J. Cancer 2012, 3:137-144.
19. Kim K.C., Koh Y.W., Chang H.M., et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann. Surg. Oncol. 2011, 18(10):2833-2840.
20. Mayr D., Heim S., Weyrauch K., et al. Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology 2009, 55:716-723.
21. García-García E., Gómez-Martín C., Angulo B., et al. Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathology 2011, 59(1):8-17.
22. Hechtman J.F., Polydorides A.D. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch. Pathol. Lab. Med. 2012, 136(6):691-697.
23. Boers J.E., Meeuwissen H., Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 2009, 58(3):383-394.
24. Haas M., Buttner M., Rau T.T., et al. Inflammation in gastric adenocarcinoma of the cardia: how do EBV infection, Her2 amplification and cancer progression influence tumor-infiltrating lymphocytes?. Virchows Arch. 2011, 458(4):403-411.
25. Fassan M., Mastracci L., Grillo F., et al. Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology 2012, 61(5):769-776.
26. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25:118-145.
27. Cho E.Y., Srivastava A., Park K., et al. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. Pathology 2012, 44(3):216-220.
28. Marx A.H., Tharun L., Muth J., et al. HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 2009, 40:769-777.
29. Yan S.Y., Hu Y., Fan J.G., et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J. Gastroenterol. 2011, 17:1501-1506.
30. Jain S., Filipe M.I., Gullick W.J., et al. c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. Int. J. Cancer 1991, 48:668-671.
31. Kunz P.L., Mojtahed A., Fisher G.A., et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl. Immunohistochem. Mol. Morphol. 2012, 20(1):13-24.
32. Yu G.Z., Chen Y., Wang J.J. Overexpression of erb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J. Cancer Res. Clin. Oncol. 2009, 135:1331-1339.
33. Barros-Silva J.D., Leitao D., Afonso L., et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br. J. Cancer 2009, 100:487-493.